- Tacrosolv eye drops, a low-dose, aqueous Marinosolv-enabled formulation of Tacrolimus, are safe and effective in alleviating symptoms of allergic rhinoconjunctivitis
- Data from phase II dose-finding clinical trial have been published in peer-reviewed Clinical Ophthalmology journal
- Tacrosolv offers great potential in treatment of inflammatory diseases of the ocular surface
The full press release is available here: